Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 4
2005 6
2006 10
2007 27
2008 36
2009 31
2010 30
2011 32
2012 32
2013 29
2014 38
2015 35
2016 35
2017 36
2018 48
2019 47
2020 30
Text availability
Article attribute
Article type
Publication date

Search Results

459 results
Results by year
Filters applied: . Clear all
Page 1
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Feagan BG, et al. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773. N Engl J Med. 2016. PMID: 27959607 Free article. Clinical Trial.
BACKGROUND: Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. ...CONCLUSIONS: Amon …
BACKGROUND: Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated a …
IL-23 in inflammatory bowel diseases and colon cancer.
Neurath MF. Neurath MF. Cytokine Growth Factor Rev. 2019 Feb;45:1-8. doi: 10.1016/j.cytogfr.2018.12.002. Epub 2018 Dec 12. Cytokine Growth Factor Rev. 2019. PMID: 30563755 Review.
Studies in recent years have identified a pivotal role of the cytokine IL-23 in the pathogenesis of inflammatory bowel diseases (IBD: Crohn´s disease, ulcerative colitis) and colitis-associated colon cancer. ...Consistently, neutralizing antibodies against …
Studies in recent years have identified a pivotal role of the cytokine IL-23 in the pathogenesis of inflammatory bowel disease …
Targeting IL-23 in Crohn's disease.
Sedda S, Bevivino G, Monteleone G. Sedda S, et al. Expert Rev Clin Immunol. 2018 Nov;14(11):907-913. doi: 10.1080/1744666X.2018.1524754. Epub 2018 Sep 24. Expert Rev Clin Immunol. 2018. PMID: 30223688 Review.
Interleukin (IL)-23, a cytokine produced by antigen presenting cells, targets both T cells and non-T cell types with the downstream effect of enhancing inflammatory pathways. Genome-wide association studies and data from human and mouse models of intestinal i
Interleukin (IL)-23, a cytokine produced by antigen presenting cells, targets both T cells and non-T cell types with th
Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
Deepak P, Sandborn WJ. Deepak P, et al. Gastroenterol Clin North Am. 2017 Sep;46(3):603-626. doi: 10.1016/j.gtc.2017.05.013. Gastroenterol Clin North Am. 2017. PMID: 28838418 Review.
We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe Crohn's disease. The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab …
We have proposed an algorithm for positioning the use of ustekinumab among other agents (TNF antagonists, vedolizumab) in moderate-severe …
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.
Moschen AR, Tilg H, Raine T. Moschen AR, et al. Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):185-196. doi: 10.1038/s41575-018-0084-8. Nat Rev Gastroenterol Hepatol. 2019. PMID: 30478416 Review.
Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including in Europe, the USA, Canada and Japan, whilst agents targeting IL-23 specifically are in late-phase clinical trials. We r …
Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, incl …
Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases.
Bunte K, Beikler T. Bunte K, et al. Int J Mol Sci. 2019 Jul 10;20(14):3394. doi: 10.3390/ijms20143394. Int J Mol Sci. 2019. PMID: 31295952 Free PMC article. Review.
In addition, Th17 cells, their key cytokine IL-17, and IL-23 seem to play pivotal roles. This review aims to provide an overview of the current knowledge about the differentiation of Th17 cells and the role of the IL-17/IL-23 axis in the …
In addition, Th17 cells, their key cytokine IL-17, and IL-23 seem to play pivotal roles. This review aims to provide an …
Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U, Cross RK. Wong U, et al. Expert Opin Investig Drugs. 2019 May;28(5):473-479. doi: 10.1080/13543784.2019.1597053. Epub 2019 Mar 26. Expert Opin Investig Drugs. 2019. PMID: 30884245 Review.
INTRODUCTION: Blockade of interleukin (IL)-12 and IL-23 is a novel therapeutic target for inflammatory bowel disease (IBD). The monoclonal antibody targeting the shared p40 subunit of IL-12 and IL23, namely ustekinumab, has been approved …
INTRODUCTION: Blockade of interleukin (IL)-12 and IL-23 is a novel therapeutic target for inflammatory bowel …
Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.
Frieder J, Kivelevitch D, Haugh I, Watson I, Menter A. Frieder J, et al. Clin Pharmacol Ther. 2018 Jan;103(1):88-101. doi: 10.1002/cpt.893. Epub 2017 Oct 19. Clin Pharmacol Ther. 2018. PMID: 28960267 Review.
Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)-23 and IL-17 as fundamental contributors in the immune pathways of the disease. ...Here we review the IL-23/IL-17 immune pathways and discu …
Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)-23 and IL-17 as fundamental …
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S. van Vollenhoven RF, et al. Lancet. 2018 Oct 13;392(10155):1330-1339. doi: 10.1016/S0140-6736(18)32167-6. Epub 2018 Sep 21. Lancet. 2018. PMID: 30249507 Clinical Trial.
BACKGROUND: Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. IL-12 and IL-23 have been impli …
BACKGROUND: Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the …
Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease.
Macaluso FS, Orlando A, Cottone M. Macaluso FS, et al. Expert Opin Biol Ther. 2019 Feb;19(2):89-98. doi: 10.1080/14712598.2019.1561850. Epub 2018 Dec 27. Expert Opin Biol Ther. 2019. PMID: 30571147 Review.
INTRODUCTION: Blockers of IL-12/23, as well as specific blockers of IL-23, have been investigated as options for medical therapy in inflammatory bowel disease. ...AREAS COVERED: This review will focus on the rationale of the blockade of IL
INTRODUCTION: Blockers of IL-12/23, as well as specific blockers of IL-23, have been investigated as options for …
459 results
Jump to page
Feedback